Faster global financial news!
Natera
-
Duquesne, the family office of Stanley Druckenmiller, has made Natera (NTRA) its top holding for eight consecutive quarters.
Duquesne, the family office of renowned investor Stanley Druckenmiller, has listed healthcare diagnostics company Natera (NASDAQ: NTRA) as its largest holding for eight consecutive quarters. Natera sp
-
Billionaire Stanley Druckenmiller made cancer-testing firm Natera (NTRA) his largest holding, increasing stake in Q2 to $864.9 million, accounting for 16.6% of his reported portfolio.
Druckenmiller's Duquesne Family Office's latest 13F filing, dated August 14, 2026, revealed Natera as his top pick, with an additional 122,700 shares bought in Q2. He views Natera's Signatera cancer-t
-
Natera (NTRA) stock surged after reporting "blowout" Q2 results, driven by strong Signatera cancer test volume
An analyst noted "blowout volume" for Natera's Signatera cancer-detecting blood test in the second quarter, which saw 34,000 tests performed.
-
Hedge fund manager Stanley Druckenmiller has allocated 18% of his $3.4 billion portfolio to the genetic testing company Natera.
According to the latest 13-F filing, legendary hedge fund manager Stanley Druckenmiller, through his family office, increased his stake in genetic testing company Natera (Nasdaq: NTRA), making it the
-
Duquesne, the family office of Stanley Druckenmiller, has made Natera (NTRA) its top holding for eight consecutive quarters.
Duquesne, the family office of renowned investor Stanley Druckenmiller, has listed healthcare diagnostics company Natera (NASDAQ: NTRA) as its largest holding for eight consecutive quarters. Natera sp
-
Billionaire Stanley Druckenmiller made cancer-testing firm Natera (NTRA) his largest holding, increasing stake in Q2 to $864.9 million, accounting for 16.6% of his reported portfolio.
Druckenmiller's Duquesne Family Office's latest 13F filing, dated August 14, 2026, revealed Natera as his top pick, with an additional 122,700 shares bought in Q2. He views Natera's Signatera cancer-t
-
Natera (NTRA) stock surged after reporting "blowout" Q2 results, driven by strong Signatera cancer test volume
An analyst noted "blowout volume" for Natera's Signatera cancer-detecting blood test in the second quarter, which saw 34,000 tests performed.
-
Hedge fund manager Stanley Druckenmiller has allocated 18% of his $3.4 billion portfolio to the genetic testing company Natera.
According to the latest 13-F filing, legendary hedge fund manager Stanley Druckenmiller, through his family office, increased his stake in genetic testing company Natera (Nasdaq: NTRA), making it the
- No data
Natera
24H Trending
-
1
SCIX Token Analysis: The Synthetic Asset Platform Token Based on Binance Smart Chain and Its Market Status
-
2
SK Hynix is down 5.5% from its previous close, now trading at ₩1,391,000.
-
3
Pi Network Withdrawal Status and Common Scams Analysis
-
4
Mainstream Cryptocurrency Exchange Registration Guide: How to Start Trading Bitcoin
-
5
What is SHFT? Shyft Network Project and Current Trading Activity
-
6
INTL Coin Intellium: An Investment Platform Combining Real Estate and Blockchain
-
7
Dogecoin Secure Trading Platforms Analysis: Selection Guide and Mainstream Options
-
8
Antminer S9 Retirement: Bitcoin Hashrate Doesn't Plummet, Continues to Grow
-
9
A Review of Major Global Digital Currency Trading Platforms and Market Landscape
-
10
Current State of Bitcoin Regulation in Mainland China: No Legitimate Trading Platforms or Apps Exist
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
